Multimodal Hyperspectroscopy with LuViva® for Detection of CIN2+ in Women Referred for Colposcopy: A Prospective Diagnostic Accuracy Study

Objectives: This study aims to evaluate the diagnostic performance of multimodal hyperspectral spectroscopy (MHS) using the LuViva® Advanced Cervical Scan for the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women referred for further cervical assessment. Methods: This prospective, non-randomized diagnostic study included 77 women examined between September 2025 and April 2026. Participants were referred because of abnormal liquid-based cytology (LBC), high-risk human papillomavirus (HR-HPV) infection, or other indications for colposcopy. LuViva examination was performed before colposcopy with cervical biopsy. Histopathological diagnosis based on biopsy or loop electrosurgical excision procedure specimens was used as the reference standard. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated for HR-HPV testing, LBC, and different LuViva positivity thresholds. Results: The mean age was 39.0 ± 8.4 years. The final histopathology showed no lesions in 30 women, LSIL in 18, HSIL in 28, and cervical cancer in one. For CIN2+ detection, HR-HPV testing demonstrated a sensitivity of 93.1% and specificity of 29.2%, whereas LBC had a sensitivity of 82.8% and specificity of 39.6%. LuViva testing showed sensitivities between 82.8% and 100%, and a specificity—when comparing with LBC—of 45.8% but 20.8% in LuViva alone. LuViva results differ significantly between women with CIN2+ and those with LSIL or no lesions. Conclusions: LuViva showed potential as an adjunctive triage tool, as no CIN2+ lesions were observed among women with a low-risk result; however, the small number of negative tests and wide confidence intervals preclude safely deferring colposcopy. The AND strategy showed a modest numerical improvement in specificity and overall accuracy compared with LBC alone but did not show an increase in sensitivity; this finding should be considered exploratory.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-10-09
DOI
https://doi.org/10.3390/cancers18203249
Primary Topic
Cervical Cancer and HPV Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multimodal Hyperspectroscopy with LuViva® for Detection of CIN2+ in Women Referred for Colposcopy: A Prospective Diagnostic Accuracy Study

Dominik Pruski, Marcin Przybylski, Sonja Millert-Kalińska
Cancers
Cervical Cancer and HPV Research
article

Multimodal Hyperspectroscopy with LuViva® for Detection of CIN2+ in Women Referred for Colposcopy: A Prospective Diagnostic Accuracy Study

Dominik Pruski, Marcin Przybylski, Sonja Millert-Kalińska
article en

Abstract

Objectives: This study aims to evaluate the diagnostic performance of multimodal hyperspectral spectroscopy (MHS) using the LuViva® Advanced Cervical Scan for the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women referred for further cervical assessment. Methods: This prospective, non-randomized diagnostic study included 77 women examined between September 2025 and April 2026. Participants were referred because of abnormal liquid-based cytology (LBC), high-risk human papillomavirus (HR-HPV) infection, or other indications for colposcopy. LuViva examination was performed before colposcopy with cervical biopsy. Histopathological diagnosis based on biopsy or loop electrosurgical excision procedure specimens was used as the reference standard. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated for HR-HPV testing, LBC, and different LuViva positivity thresholds. Results: The mean age was 39.0 ± 8.4 years. The final histopathology showed no lesions in 30 women, LSIL in 18, HSIL in 28, and cervical cancer in one. For CIN2+ detection, HR-HPV testing demonstrated a sensitivity of 93.1% and specificity of 29.2%, whereas LBC had a sensitivity of 82.8% and specificity of 39.6%. LuViva testing showed sensitivities between 82.8% and 100%, and a specificity—when comparing with LBC—of 45.8% but 20.8% in LuViva alone. LuViva results differ significantly between women with CIN2+ and those with LSIL or no lesions. Conclusions: LuViva showed potential as an adjunctive triage tool, as no CIN2+ lesions were observed among women with a low-risk result; however, the small number of negative tests and wide confidence intervals preclude safely deferring colposcopy. The AND strategy showed a modest numerical improvement in specificity and overall accuracy compared with LBC alone but did not show an increase in sensitivity; this finding should be considered exploratory.

CancersVol. 18(20)
Poznan University of Medical Sciences (PL)
Openalex Percentile: Top 12%
Cervical Cancer and HPV Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.